Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for Gossamer Bio in a research note issued on ...

周二，H.C. Wainwright重申对Gossamer Bio ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareho ...

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a report released on Friday ...

Gossamer Bio ( ($GOSS) ) has released its Q4 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ: GOSS) saw its shares climb 5.4% after the biopharmaceutical company reported better-than-expected fourth quarter results and provided updates on its pulmonary ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...

On a per-share basis, the San Diego-based company said it had a loss of 15 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

Cash, cash equivalents and marketable securities as of December 31, 2024, were $294.5 million. As a result, we expect our ...

EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...